ArticleTranslational andrology and urology2025
Molecular insights into treatment-resistant erectile dysfunction: staining patterns of human corpora cavernosa-a preliminary study.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with end-stage erectile dysfunction (ED) who fail to respond to phosphodiesterase-5 inhibitors lack well-defined molecular targets for new pharmacologic therapies. To identify common expression patterns of key biomarkers in corpora cavernosa tissue from men undergoing penile prosthesis placement, thereby informing future drug development for treatment-resistant ED. Methods: Formalin-fixed corpora cavernosa specimens were collected intraoperatively from 14 men receiving penile prostheses for ED. Sections were immunohistochemically stained for Rho-associated protein kinase (ROCK1/ROCK2), CD31 (endothelial marker), smooth muscle actin (SMA), and lysyl oxidase (LOX1). Staining intensity was graded under light microscopy on a 0 to +4 scale: 0 (negative), +1 (weak/mild), +2 (moderate), +3 (strong), and +4 (intense). Baseline demographics and comorbidities were recorded. Results: Older age, longer ED duration, hypertension, hyperlipidemia, and coronary artery disease were associated with higher ROCK1/2 expression. SMA staining was elevated in hypertensive patients and those with prolonged ED. Both current and former smokers showed increased CD31 expression, while LOX1 levels were highest in subjects with coronary artery disease. Across all samples, mean scores for ROCK1/2 and SMA exceeded those for CD31 and LOX1. Conclusions: This preliminary analysis reveals differential expression of four biomarkers in treatment-resistant ED associated with specific comorbidities. ROCK1/2- and SMA-driven pathways may represent promising targets for new ED therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.